[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mechanical-ventilation-pressure-high\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mechanical-ventilation-pressure-high":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,69,92,118,143,166,191],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100473127","platform-of-randomized-adaptive-clinical-trials-in-critical-illness-100473127",false,"NCT05440851","Platform of Randomized Adaptive Clinical Trials in Critical Illness","PRACTICAL","PRACTICAL Platform Inclusion Criteria:\n\n1. Acute hypoxemic respiratory failure meeting all of the following criteria;\n\n   1. New or worsening respiratory symptoms developing within 2 weeks prior to the onset of need for oxygen or respiratory support\n   2. Receiving any of the following types of oxygen or respiratory support for at least 4 hours prior to the time of randomization; supplemental oxygen at 10 L\u002Fmin or higher, high flow nasal oxygen (at any flow rate), invasive ventilator support, extra-corporeal life support (ECLS), or non-invasive ventilator support\n   3. Minimum FiO2 ≥ 0.40 (for venturi mask, high flow nasal cannula, or invasive or non-invasive ventilation) or oxygen flow rate ≥10 L\u002Fmin on face mask for at least 4 hours at the time of evaluation for eligibility unless already on extra-corporeal life support\n2. Age ≥ 18 years\n3. Hypoxemia not primarily attributable to acute heart failure, fluid overload, or pulmonary embolism (PE)\n\nPRACTICAL Platform Exclusion Criteria:\n\n1. Extubation is planned or anticipated on the day of screening\n2. ICU discharged is planned or anticipated on the day of screening\n3. If the patient is moribund and deemed unlikely to survive 24 hours (as determined by the clinical team)\n4. If the patient is being transitioned to a fully palliative philosophy of care\n\nEXPAND-ECLS Domain Inclusion Criteria:\n\n1. Receiving invasive Endotracheal mechanical ventilation for ≤ 72 hours.5 days\n2. Early Moderate-severe hypoxemic respiratory failure with a PaO2\u002FFiO2≤150200 mmHg for at least 6 hours\n\nEXPAND-ECLS Domain Exclusion Criteria:\n\n1. Patients over 70 years of age.\n2. Currently receiving any form of ECLS (e.g., Venovenous, venoarterial, or hybrid configuration).\n3. Chronic hypercapnic respiratory failure defined as PaCO2 \\> 60 mmHg in the outpatient setting.\n4. Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for CPAP\u002FBiPAP used solely for sleep-disordered breathing.\n5. Actual body weight exceeding 1 kg per centimeter of height.\n6. More than 48 hours have passed since meeting inclusion criteria.\n7. Severe hypoxemia with PaO2\u002FFiO2 \\\u003C 80mmHg for \\> 6 hours at time of screening.\n8. Severe hypercapnic respiratory failure with pH \\\u003C 7.25 and PaCO2 \\> 60 mmHg for \\> 6 hours at time of screening.\n9. Expected mechanical ventilation duration \\\u003C 48 hours at time of screening.\n10. Confirmed diffuse alveolar hemorrhage from vasculitis.\n11. Contraindications to limited anticoagulation (e.g., active GI bleeding, bleeding diathesis).\n12. Previous hypersensitivity\u002Fanaphylactic reaction to heparin or heparin-induced thrombocytopenia\n13. Neurologic conditions at risk for or undergoing treatment for intracranial hypertension\n14. Underlying illness with life expectancy \\\u003C 1 year\n15. Pregnancy (due to unknown effects of PaCO2 changes on placental blood flow)\n16. Respiratory failure known or suspected to be caused by COVID-19.\n\nIMV Domain Inclusion Criteria:\n\n1. Intubated patients, not on ECLS, with low normalized respiratory elastance (\\\u003C2.5 cm H2O\u002F(ml\u002Fkg predicted body weight)) at the time of eligibility assessment OR\n2. Intubated patients, not on ECLS, with high normalized respiratory system elastance (≥2.5 cm H2O\u002F(ml\u002Fkg predicted body weight)) at the time of eligibility assessment OR\n3. FOR STUDY SITES PARTICIPATING IN THE LDPVS INTERVENTION: Patient is on ECLS at the time of eligibility assessment. Note: Patients in this state are only eligible for the LPV or LDPVS intervention\n4. FOR STUDY SITES PARTICPATING IN THE EIT INTERVENTION: PaO2\u002FFiO2 (if available) \\\u003C 200 mm Hg at randomization. If PaO2\u002FFiO2 has not been measured, SpO2 = 97% on FiO2 =60%.\n\nIMV Domain Exclusion Criteria:\n\n1. PaO2\u002FFiO2 \\>300 mm Hg or (S\u002FF \\>250, if PaO2\u002FFiO2 has not been measured) at the time of randomization\n2. Chronic hypercapnic respiratory failure defined as PaCO2\\>60mmHg in the outpatient setting\n3. Home mechanical ventilation (non-invasive ventilation or via tracheotomy), not including nocturnal CPAP applied by nasal or face mask or home tracheotomy if not ventilated\n4. Severe hypoxemia with PaO2\u002FFiO2\\\u003C80mmHg for \\>6 consecutive hours at the time of randomization\n5. Severe hypercapnic respiratory failure with pH\\\u003C7.25 and PaCO2\\>60mmHg for \\>6 consecutive hours at the time of randomization\n6. Anticipated duration of mechanical ventilation is \\\u003C48 hours from the time of screening\n7. Duration of mechanical ventilation during current ICU admission is \\>72 hours\n8. Previously diagnosed neuromuscular disorder\n9. Current diagnosis of severe acute brain injury (e.g. ischemic or hemorrhagic stroke, traumatic brain injury) with Glasgow Coma Scale ≤ 8\n10. Baseline weight prior to or at hospital admission less than 35 kilograms\n11. Receiving extracorporeal life support without continuous invasive mechanical ventilatory support\n\nCORT-E2 Domain Early Cohort Inclusion Criteria\n\n1. Within 72 hours of admission to an ICU\n2. New unilateral or bilateral airspace disease\n\nCORT-E2 Domain Early Domain Exclusion Criteria\n\n1. Receiving only low flow oxygen therapy less than or equal to 15L\u002Fmin\n2. Corticosteroid use during the 14 days prior to screening\n3. Existing indication for corticosteroids\n4. High suspicion for\u002For confirmed COVID infection\n5. Acute traumatic brain injury during the index hospital admission\n6. Allergy to dexamethasone\n\nCORT-E2 Domain Extended Cohort Inclusion Criteria\n\n1. Are admitted to an ICU\n2. Have already received 10 days of corticosteroid specifically for acute respiratory failure, this will include patients: (a) randomized to corticosteroid arm in Early Cohort, (b) patients with COVID receiving corticosteroids as standard of care , (c) and others who have received corticosteroids for AHRF\n3. Ongoing AHRF requiring HFNC, NIV (continuous positive airway pressure \\[CPAP\\] or bilevel) or invasive ventilation\n\nCORT-E2 Domain Extended Cohort Exclusion Criteria\n\n1. An alternate indication for ongoing corticosteroids\n2. Acute traumatic brain injury this hospital admission\n\nFLUDRO Domain Inclusion Criteria 1. Within 72 hours of admission to an ICU\n\nFLUDRO Domain Exclusion Criteria\n\n1. Known hypersensitivity to fludrocortisone\n2. An inability to receive fludrocortisone due to lack of enteral access\n3. An indication to prescribe fludrocortisone for a reason that is unrelated to a current episode of pneumonia or acute respiratory failure, such as Addison's disease\n4. Belief of the treating clinical team that study participation would not be in the best interest of the patient\n\nFAST-3 Domain Inclusion Criteria (must meet all 3 of the following)\n\n1. Patient is in a PRACTICAL eligible platform state and requires advanced respiratory support (ARS) defined as one of the following:\n\n   a. Invasive mechanical ventilation with FiO2 \\> 40% b. Non-Invasive Ventilation (\\> 4 hours consecutively with FiO2 \\> 40%) defined as: i. CPAP or BiPAP (any settings or interface) ii. HFNC (flow \\> 40 liter per minute)\n2. PaO2\u002FFiO2 \\\u003C 300 mm Hg or SpO2\u002FFiO2 \\\u003C 315 (if PaO2\u002FFiO2 unavailable due to lack of arterial blood gas at the time of screening). For SpO2\u002FFiO2, criteria are SpO2 ≤ 97% on FiO2 ≥ 40% on both of the 2 hours immediately preceding eligibility assessment. If an arterial blood gas can be obtained, then a PaO2\u002FFiO2 ratio is preferable.\n3. Patient commenced advanced respiratory support \\\u003C 48 hours prior to randomization.\n\nFAST-3 Domain Exclusion Criteria\n\n1. Patient commenced advanced respiratory support \\> 48 hours to time of randomization.\n2. Known history of severe chronic pulmonary disease e.g., pre-infection requirement for home oxygen therapy or presence of chronic hypercapnia (PaCO2 \\> 60 mmHg); mild - moderate disease is still eligible in the absence of chronic hypercapnia or need for chronic oxygen therapy.\n3. Currently enrolled in another trial studying investigational anti-inflammatory therapy, excluding established treatments used in clinical practice such as corticosteroids.\n4. Known allergy to furosemide or sulfonamide drugs. If the patient is allergic to sulfonamide drugs but has received in the past or is currently receiving furosemide without incident, they can be enrolled since cross-reactivity between furosemide and sulfonamide agents is rare.\n\nESCAPE Domain Inclusion Criteria\n\n1. Patients with severe AHRF who have an underlying immunocompromised condition\n2. Within 48 hours of fulfilling the AHRF inclusion criteria as well as PaO2\u002FFiO2 \\\u003C300 or a SaO2\u002FFiO2 \\\u003C 315 on non-invasive respiratory support (venturi mask, non-invasive ventilation or high flow nasal oxygen as per the FiO2 requirements above) or invasive ventilation.\n\nPatients may be enrolled from the wards or ICU.\n\nImmunocompromised patients include:\n\n1. Any patients requiring long term (\\>30 days) corticosteroids (\\>20 mg\u002Fday),\n2. Any patients receiving non-corticosteroid immunosuppressive medications within the prior 3 months,\n3. Acquired or inherited immunodeficiency syndrome,\n4. Recipients of solid organ transplant,\n5. Active hematologic malignancy (diagnosis or receiving treatment within prior 6 months),\n6. Active solid tumor (diagnosis or receiving treatment within the prior 6 months) or\n7. Any patients who have undergone allogeneic or autologous hematopoietic cell transplant in the prior 6 months (HCT).\n\n   ESCAPE Domain Exclusion Criteria\n   1. Patients whom are deemed palliative.\n\n   WAVEFORM Domain Inclusion Criteria\n\n   1\\. Patient is intubated at the time of eligibility assessment.\n\n   WAVEFORM Domain Exclusion Criteria\n   1. PaO2\u002FFiO2 \\>300 mm Hg or (S\u002FF \\>250, if PaO2\u002FFiO2 has not been measured) at the time of eligibility assessment.\n   2. Duration of mechanical ventilation during current ICU admission is ≥72 hours.\n   3. Receiving ECLS without continuous invasive mechanical ventilatory support.\n\n   IMV-ECLS Domain Inclusion Criteria\n\n   1\\. Patients with AHRF (as defined in platform inclusion criteria #1 above) who have been consented for cannulation for VV-ECLS or who have been initiated on VV-ECLS within 6 hours at the time of randomization\n\n   IMV-ECLS Domain Exclusion Criteria 1. Patients receiving ECLS for the primary intention of extracorporeal CO2 removal 2. Patients expected to be liberated from ECLS within \\\u003C24 hours 3. History of recent pneumothorax or pneumomediastinum (\\\u003C3 months at the time of eligibility assessment\u002Frandomization) 4. Patients receiving ECLS for the primary intention of bridge to lung transplantation (at the time of eligibility assessment\u002Frandomization)\n\n   IMPROV Domain Inclusion Criteria\n   1. Patients receiving invasive mechanical ventilation for AHRF as defined by the PRACTICAL platform trial criteria above.\n   2. Within 7 calendar days of intubation\n\n   IMPROV Domain Exclusion Criteria\n   1. Patient is expected to be liberated from mechanical ventilation within 24 hours\n   2. Known or suspected chronic hypercapnic respiratory failure defined as PaCO2\\>60mmHg in the outpatient setting\n   3. Home mechanical ventilation (non-invasive ventilation or via tracheotomy), not including nocturnal CPAP applied by nasal or face mask or home tracheotomy if not ventilated\n   4. Known pneumothorax or pneumomediastinum without chest tube placement sustained during current ICU admission\\* (re-confirm immediately prior to randomization)\n   5. Patient is admitted primarily for acute brain injury (stroke, traumatic brain injury, etc.)\n   6. Previously diagnosed chronic neuromuscular disorder\n   7. Patient has an implantable cardiac defibrillator or pacemaker\n   8. Planned to be transferred to another hospital before ICU discharge\n   9. Already receiving a regimen of inspiratory muscle training using external resistive device or diaphragm neurostimulation","ALL","18 Years",{"count":19,"type":20},6250,"ESTIMATED","INTERVENTIONAL",[23],"NA","PRACTICAL is a randomized multifactorial adaptive platform trial for acute hypoxemic respiratory failure (AHRF). This platform trial will evaluate novel interventions for patients with AHRF across a range of severity states (i.e., not intubated, intubated with lower or higher respiratory system elastance, requiring extracorporeal life support) and across a range of investigational phases (i.e., preliminary mechanistic trials, full-scale clinical trials). AHRF is a common and life-threatening clinical syndrome affecting millions globally every year. Patients with AHRF are at high risk of death and long-term morbidity. Patients who require invasive mechanical ventilation are at risk of ventilator-induced lung injury and ventilator-induced diaphragm dysfunction. New treatments and treatment strategies are needed to improve outcomes for these very ill patients.\n\nUtilizing advances in Bayesian adaptive trial design, the platform will facilitate efficient yet rigorous testing of new treatments for AHRF, with a particular focus on mechanical ventilation strategies and extracorporeal life support techniques as well as pharmacological agents and new medical devices.\n\nThe platform is designed to enable evaluation of novel interventions at a variety of stages of investigation, including pilot and feasibility trials, trials focused on mechanistic surrogate endpoints for preliminary clinical evaluation, and full-scale clinical trials assessing the impact of interventions on patient-centered outcomes.\n\nA domain is defined as a set of interventions that are intended to act on specific mechanisms of injury using different variations of a common therapeutic strategy. A domain may also be a non-interventional study that addresses observational research questions by collecting specific data or outcomes that are not collected as part of other domains. Domains are intended to function independently of each other, allowing independent evaluation of multiple therapies and mechanistic pathways within the same patient.\n\nOnce feasibility is established, Bayesian adaptive statistical modelling will be used to evaluate treatment efficacy at regular interim adaptive analyses of the pre-specified outcomes for each intervention in each domain. These adaptive analyses will compute the posterior probabilities of superiority, futility, inferiority, or equivalence for pre-specified comparisons within domains. Each of these potential conclusions will be pre-defined prior to commencing the intervention trial. Decisions about trial results (e.g., concluding superiority or equivalence) will be based on pre-specified threshold values for posterior probability. The primary outcome of interest, the definitions for superiority, futility, etc. (i.e., the magnitude of treatment effect) and the threshold values of posterior probability required to reach conclusions for superiority, futility etc., will vary from intervention to intervention depending on the phase of investigation and the nature of the intervention being evaluated. All of these parameters will be pre-specified as part of the statistical design for each intervention trial.\n\nIn general, domains will be designed to evaluate treatment effect within four discrete clinical states: non-intubated patients, intubated patients with low respiratory system elastance (\\\u003C2.5 cm H2O\u002F(mL\u002Fkg)), intubated patients with high respiratory system elastance (≥2.5 cm H2O\u002F(mL\u002Fkg)), and patients requiring extracorporeal life support. Where appropriate, the model will specify dynamic borrowing between states to maximize statistical information available for trial conclusions. In this perpetual trial design, different interventions may be added or dropped over time.\n\nWhere possible, the platform will be embedded within existing data collection repositories to enable greater efficiency in outcome ascertainment. Standardized systems for acquiring both physiological and biological measurements are embedded in the platform, to be acquired at sites with appropriate training, expertise, and facilities to collect those measurements.",[26,27,28],"Respiratory Insufficiency","Extracorporeal Membrane Oxygenation Complication","Mechanical Ventilation Pressure High","RECRUITING","2026-05-01",{"date":32,"type":33},"2026-05-07","ACTUAL",{"date":35,"type":33},"2023-04-30",{"date":37,"type":20},"2027-03-31",{"name":39,"class":40},"University Health Network, Toronto","OTHER",89,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100621826","dynamic-airway-resistance--ml-guide-sputum-suction-in-ventilated-patients-100621826","NCT07375667","Dynamic Airway Resistance & ML: Guide Sputum Suction in Ventilated Patients","Mechanisms of Dynamic Airway Resistance Monitoring and Machine Learning for Assessing Pulmonary Inflammation and Guiding Sputum Suction in Mechanically Ventilated Patients","Inclusion Criteria:\n\n* Clinical diagnosis of Acute Respiratory Distress Syndrome (ARDS)\n* Clinical diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)\n* Clinical diagnosis of Severe pneumonia\n\nExclusion Criteria:\n\n* Clinical diagnosis of multiple organ failure;\n* Clinical diagnosis of multiple organ bleeding;","90 Years",{"count":51,"type":20},258,[23],"Research has shown that timely suctioning not only improves survival rates but also enhances the quality of life in ventilator-dependent patients. However, clinical judgment on the optimal timing for suctioning currently relies primarily on physician experience, lacking scientific evidence \\[10\\]. Airway viscous resistance reflects the frictional resistance encountered by gas flow within the airways and is closely associated with airway patency. When airway secretions increase, viscous resistance undergoes dynamic changes. Therefore, analyzing these dynamic variations in viscous resistance derived from ventilator waveforms to determine the optimal suctioning timing and assess its clinical impact on the progression of pulmonary inflammation holds significant scientific value and offers new insights and methodologies for clinical practice.",[28,55,56],"Ventilator-Associated Pneumonia (VAP)","Respiratory Depression Neonatal",[58],"Airway resistance","2026-01-26",{"date":61,"type":33},"2026-01-29",{"date":63,"type":33},"2025-10-30",{"date":65,"type":20},"2029-12-30",{"name":67,"class":40},"Affiliated Hospital of Nantong University",3,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100446844","end-expiratory-trans-pulmonary-pressure-guided-peep-titration-in-patients-with-pulmonary-fibrosis-and-uip-pattern-undergoing-mechanical-ventilation-100446844","NCT05098717","End-expiratory Trans-pulmonary Pressure Guided PEEP Titration in Patients With Pulmonary Fibrosis and UIP Pattern Undergoing Mechanical Ventilation","ETROPON","Inclusion Criteria:\n\n* pulmonary fibrosis with UIP pattern\n* subjected to endotracheal intubation and controlled mechanical ventilation for acute respiratory failure\n* candidate to a trial of PEEP titration according to positive end expiratory pressure.\n\nExclusion Criteria:\n\n* chest wall deformities\n* chronic obstructive pulmonary disease",{"count":77,"type":20},40,"OBSERVATIONAL","Patients with pulmonary fibrosis and associated usual interstitial pneumonia that require mechanical ventilation for acute respiratory failure experience poor clinical outcomes. This may be influenced by the unfavorable interaction between the fibrotic lung and the stress and strain stimuli generated during controlled ventilation. Although there is no consensus on how to ventilate these patients, much of the recommendations followed in clinical practice are taken from the experience on patients with acute respiratory distress syndrome. Among these, measuring the esophageal pressures and adjusting positive-end expiatory pressure to make trans-pulmonary pressures positive can decrease atelectasis, derecruitment of lung, and cyclical opening and closing of airways and alveoli, thus optimizing lung mechanics and oxygenation. The effect of this strategy on the fibrotic lung has not yet been documented. With this observational study we aim at documenting the effect of PEEP titration maneuver based on end-expiratory trans-pulmonary pressure on lung mechanics of patients with pulmonary fibrosis and UIP pattern,",[81,28],"Idiopathic Pulmonary Fibrosis","2025-04-24",{"date":84,"type":33},"2025-04-25",{"date":86,"type":33},"2023-02-08",{"date":88,"type":20},"2027-01-01",{"name":90,"class":40},"University of Modena and Reggio Emilia",1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":16,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":91},"100529006","effect-of-individualized-peep-on-postoperative-pulmonary-complication-in-bariatrics-100529006","NCT06168162","Effect of Individualized PEEP on Postoperative Pulmonary Complication in Bariatrics","Effect of Individualized High Positive End-expiratory Pressure on Postoperative Pulmonary Rate in Laparoscopic Bariatric Surgeries","Inclusion Criteria:\n\n* Patients were eligible for participation if the met the following criteria\n\n  * Age between 18 and 60 years old.\n  * Body mass index \\> 40\n  * Laparoscopic bariatric elective surgery under general anesthesia.\n  * ARISCAT (Assess Respiratory Risk in Surgical Patients in Catalonia) score ≥ 45 . ARISCAT score is a clinically practical seven-factor scoring system to assess the risk of a composite PPC.\n\nExclusion Criteria:\n\n* Previous lung surgery\n* ASA status III or IV.\n* Moderate to severe obstructive or restrictive lung disease .\n* Persistant intraoperative hemodynamic instability .\n* Need for postoperative mechanical ventilation",true,"16 Years",{"count":102,"type":20},50,[23],"Ventilation with low tidal volume and high PEEP (positive end expiratory pressure) has been shown to improve oxygenation in patients with ARDS (acute respiratory distress syndrome). In obese patients undergoing laparoscopic bariatric surgeries, the risk of postoperative pulmonary complications (PPCs) increases significantly with general anesthesia. Previous studies have shown that protective lung ventilation strategies could improve intraoperative oxygenation and lung mechanics.\n\nIn this study would compare the effect of optimum individualized high PEEP versus standard PEEP - on postoperative pulmonary complications",[28,106],"Bariatric Surgery Candidate",[108],"ventilation","2025-02-14",{"date":111,"type":33},"2025-02-17",{"date":113,"type":33},"2023-10-01",{"date":115,"type":20},"2025-05-01",{"name":117,"class":40},"Ain Shams University",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100559393","fcv-vs-vcv-in-obstructive-and-asthmatic-patients-100559393","NCT06563544","FCV Vs VCV in Obstructive and Asthmatic Patients","Flow Versus Volume-Controlled Ventilation in Intubated Obstructive and Asthmatic Patients","Inclusion Criteria:\n\n* 18 years or older;\n* Provided written informed consent;\n* Undergoing controlled mechanical ventilation via an endotracheal tube;\n* Reason for intubation being exacerbation of asthma or COPD;\n* Intubated ≤72 hours\n\nExclusion Criteria:\n\n* Severe sputum stasis or production requiring frequent bronchial suctioning (more than 5 times per nurse shift)\n* Untreated pneumothorax (i.e. no pleural drainage)\n* Hemodynamic instability defined as a mean arterial pressure below 60mmHg not responding to fluids and\u002For vasopressors or a noradrenalin dose \\>0.5mcrg\u002Fkg\u002Fmin\n* High (\\>15 mmHg) or instable (an increase in sedation or osmotherapy is required) intracranial pressure\n* An inner tube diameter of 6mm or less\n* Anticipating withdrawal of life support and\u002For shift to palliation as the goal of care\n* Inability to perform adequate electrical impedance tomography (EIT) measurements with, e.g.:\n\n  * Have a thorax circumference inappropriate for EIT-belt\n  * Thoracic wounds, bandages or deformities preventing adequate fit of EIT-belt\n  * Recent (\\\u003C7 days) pulmonary surgery including pneumonectomy, lobectomy or lung transplantation\n  * ICD device present (potential interference with proper functioning of the EIT device and ICD device)\n  * Excessive subcutaneous emphysema\n* Contra-indications for nasogastric tube or inability to perform adequate transpulmonary pressure measurements with, e.g.:\n\n  * Recent esophageal surgery\n  * Prior esophagectomy\n  * Known presence of esophageal varices\n  * Severe bleeding disorders","100 Years",{"count":127,"type":20},10,[23],"The goal of this physiological pilot study with a randomized crossover design is to study the effect of Flow-controlled ventilation (FCV) on the minute volume compared to Volume-controlled ventilation (VCV) in intubated patients with an exacerbation of their asthma or COPD.\n\nOur hypothesis is that FCV will results in a lower minute volume compared to VCV in this patient category.\n\nPatients will be randomized between two ventilation sequences, namely 90 minutes of FCV followed by 90 minutes of VCV or vice versa.",[131,28,132],"Obstructive Pulmonary Disease","Asthma COPD","2024-10-16",{"date":135,"type":33},"2024-10-18",{"date":137,"type":20},"2024-10",{"date":139,"type":20},"2027-10",{"name":141,"class":40},"Erasmus Medical Center",2,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":4},"100564670","non-invasive-monitoring-of-mixed-venous-oxygen-saturation-using-the-capnodynamic-method-in-adults-100564670","NCT06632197","Non-invasive Monitoring of Mixed Venous Oxygen Saturation Using the Capnodynamic Method in Adults","CAPNO-SVO2","Inclusion Criteria:\n\n* Age \\> 18 years\n* Not participating in any other interventional study at the time of the study.\n* Patients under controlled mechanical ventilation in passive conditions.\n* Situations where the responsible physician deems that, for the benefit of clinical management and therapeutic decision-making, the patient would benefit from the placement of a pulmonary artery catheter (Swan-Ganz) and\u002For monitoring of central or mixed venous saturation.\n* Obtaining informed consent.\n\nExclusion Criteria:\n\n* Failure to obtain informed consent.\n* No need for invasive mechanical ventilation.",{"count":151,"type":20},25,"The objective of this study is to compare the accuracy and correlation of the capnodynamic method for measuring mixed venous oxygen saturation (SvO2) with the standard reference method (pulmonary artery catheter), with the potential for the capnodynamic method to replace the traditional method in selected cases.",[154,155,28],"Ventilatory Failure","Cardiac Failure","NOT_YET_RECRUITING","2024-10-08",{"date":159,"type":33},"2024-10-10",{"date":161,"type":20},"2024-12",{"date":163,"type":20},"2025-08",{"name":165,"class":40},"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":174,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":91},"100546303","epidemiology-and-treatment-strategy-of-open-respiratory-phenotype-in-critically-ill-patients-100546303","NCT06393179","Epidemiology and Treatment Strategy of Open Respiratory Phenotype in Critically Ill Patients","Inclusion Criteria:\n\n* Adult patients undergoing controlled mechanical ventilation\n* The duration of endotracheal intubation \\\u003C 48 hrs\n\nExclusion Criteria:\n\n* Severe hemodynamic instability\n* Severe chronic lung disease requiring long-term home oxygen therapy\n* Patients without analgesic sedation\n* Decline to participate in the study\n* Refusal to sign informed consent",{"count":173,"type":20},60,[23],"Monitoring airway pressure is essential for patients with mechanical ventilation. However, static airway pressure does not reflect alveolar pressure at all. Airway pressure is supposed to completely interrupt the communication between proximal airway opening and the distal alveolar and\u002For small airway structures. In this condition, some alveoli may still be inflated but do not communicate with proximal airways and auto-PEEP will give a biased estimated of mean alveolar pressure. To be note, distinguishing the airway closure and alveolar collapse can be challenging at times. The quasi-static PV curve is a useful bedside tool to set mechanical ventilation, which may help us to identify the airway closure and alveolar collapse. Meanwhile, the quasi-static PV curve can only reflects a global behaviour of the lung, while EIT may be a useful tool to assess the regional information on airway closure and alveolar collapse.",[28,177],"Critical Illness",[179,180,181],"mechanical ventilation","airway closure","alveolar collapse","2024-08-13",{"date":184,"type":33},"2024-08-16",{"date":186,"type":33},"2024-05-30",{"date":188,"type":20},"2024-08-30",{"name":190,"class":40},"Southeast University, China",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":91},"100551756","extremes-of-respiratory-effort-in-weaning-failure-from-mechanical-ventilation-a-prospective-observational-study-100551756","NCT06464224","Extremes of Respiratory Effort in Weaning Failure From Mechanical Ventilation: a Prospective Observational Study","Are the Extremes of Respiratory Efforts During Assisted Ventilation Associated With Weaning Failure in Critical Ill Patients: a Prospective Observational Study","Inclusion Criteria:\n\n* Patients over 18 years old, admitted to the Glória D'or hospital, undergoing orotracheal intubation and invasive mechanical ventilation, in their first 7 years on spontaneous ventilation, who accept to participate in the study by signing the free and informed consent form (or by their legal responsible).\n\nExclusion Criteria:\n\n* • Neuromuscular disease;\n\n  * Phrenic nerve injury;\n  * MV for less than 24 hours;\n  * Previously tracheostomized patient;\n  * Age under 18;\n  * Use of neuromuscular blocker \\> 72h;\n  * COPD;\n  * Patients with pulmonary fibrosis;\n  * Pregnancy;\n  * Patient under palliative care;\n  * COVID-19 pneumonia;\n  * Patients reintubated after extubation in this hospitalization for less than 3 weeks.",{"count":91,"type":20},"The presence of high levels of respiratory effort in patients under mechanical ventilation may worsen the adjacent lung injury even after adapting protective ventilation. Primary outcome: To evaluate the failure rate of weaning from IMV and its relationship with the lower and upper extremes of respiratory effort and the upper extreme of dynamic pulmonary stress during the first 7 days of spontaneous ventilation. Analyze the influence of these extremes based on the thresholds of Pocc, P0.1 and their derivatives Pmus, Ptp, din and MP: in relation to days off MV (in the 28-day interval); Total weaning time; Rate and time for tracheostomy; Length of stay in the ICU and hospital; In-hospital mortality rate. CAAE: 78185823.4.0000.5249. Prospective multicenter observational study, carried out in the ICUs of Glória D'or and Niteroi D'or hospitals, from January 2024 to July 2026, in patients over 18 years old, undergoing orotracheal intubation and IMV, in their first 7 days on spontaneous ventilation. Hypothesis: Extremes of respiratory effort and dynamic pulmonary stress would be associated with a higher rate of weaning from IMV, as well as longer time on IMV and subsequent longer hospital stay.",[28,201],"Weaning Failure",[203,204],"respiratory drive","respiratory effort","2024-07-19",{"date":207,"type":33},"2024-07-23",{"date":209,"type":33},"2024-04-01",{"date":211,"type":20},"2026-07",{"name":213,"class":40},"Universidade Federal do Rio de Janeiro"]